Pulmatrix, Inc.PULMEarnings & Financial Report
Pulmatrix, Inc. is a clinical-stage biopharmaceutical firm specializing in developing innovative inhaled therapies for severe respiratory diseases including chronic obstructive pulmonary disease, cystic fibrosis and idiopathic pulmonary fibrosis. It uses its proprietary dry powder platform to improve inhaled medication efficacy and safety, advancing its product candidate pipeline via partnerships with global pharmaceutical players.
Revenue
$1.8M
Gross Profit
N/A
Operating Profit
$-3.9M
Net Profit
$-3.8M
Gross Margin
N/A
Operating Margin
-224.7%
Net Margin
-215.3%
YoY Growth
-6.4%
EPS
$-1.03
Pulmatrix, Inc. Q3 FY2023 Financial Summary
Pulmatrix, Inc. reported revenue of $1.8M (down 6.4% YoY) for Q3 FY2023, with a net profit of $-3.8M (up 25.3% YoY) (-215.3% margin).
Key Financial Metrics
| Total Revenue | $1.8M |
|---|---|
| Net Profit | $-3.8M |
| Gross Margin | N/A |
| Operating Margin | -224.7% |
| Report Period | Q3 FY2023 |
Pulmatrix, Inc. Annual Revenue by Year
Pulmatrix, Inc. annual revenue history includes year-by-year totals (for example, 2023 revenue was $7.3M).
| Year | Annual Revenue |
|---|---|
| 2023 | $7.3M |
| 2022 | $6.1M |
Pulmatrix, Inc. Quarterly Revenue & Net Profit History
Pulmatrix, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q2 FY2024 | $1.6M | -15.8% | $-5.8M | -374.4% |
| Q1 FY2024 | $5.9M | +292.6% | $825.0K | 14.0% |
| Q4 FY2023 | $2.2M | +28.9% | $-2.1M | -94.6% |
| Q3 FY2023 | $1.8M | -6.4% | $-3.8M | -215.3% |
| Q2 FY2023 | $1.8M | +38.5% | $-3.8M | -206.9% |
| Q1 FY2023 | $1.5M | +29.2% | $-4.4M | -296.7% |
| Q4 FY2022 | $1.7M | +274.6% | $-4.2M | -246.8% |
| Q3 FY2022 | $1.9M | +75.1% | $-5.1M | -269.9% |
Income Statement
| Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.9M | $1.7M | $1.5M | $1.8M | $1.8M | $2.2M | $5.9M | $1.6M |
| YoY Growth | 75.1% | 274.6% | 29.2% | 38.5% | -6.4% | 28.9% | 292.6% | -15.8% |
Balance Sheet
| Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $46.5M | $41.0M | $36.1M | $31.4M | $36.8M | $34.0M | $30.4M | $15.8M |
| Liabilities | $11.4M | $9.8M | $9.0M | $7.9M | $16.9M | $16.0M | $11.4M | $2.5M |
| Equity | $35.0M | $31.1M | $27.0M | $23.4M | $19.9M | $18.0M | $19.0M | $13.3M |
Cash Flow
| Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-3.6M | $-5.0M | $-4.9M | $-4.9M | $-4.1M | $-2.0M | $-2.7M | $-3.7M |